Anidulafungin | CAS#166663-25-8 | (1→3)-β-D-glucan synthase inhibitor

MedKoo Cat#: 314269 | Name: Anidulafungin

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Anidulafungin, also known as LY303366, is a semisynthetic echinocandin used as an antifungal drug. Anidulafungin was approved on 2/21/2006. Anidulafungin has proven efficacy against esophageal candidiasis, but its main use will probably be in invasive Candida infection; it may also have application in treating invasive Aspergillus infection. It is a member of the class of antifungal drugs known as the echinocandins; its mechanism of action is by inhibition of (1→3)-β-D-glucan synthase, an enzyme important to the synthesis of the fungal cell wall. Anidulafungin inhibits glucan synthase, an enzyme important in the formation of (1→3)-β-D-glucan, a major fungal cell wall component. Glucan synthase is not present in mammalian cells, so it is an attractive target for antifungal activity.

Chemical Structure

Anidulafungin

CAS#166663-25-8

Theoretical Analysis

MedKoo Cat#: 314269

Name: Anidulafungin

CAS#: 166663-25-8

Chemical Formula: C58H73N7O17

Exact Mass: 1139.5063

Molecular Weight: 1140.24

Elemental Analysis: C, 61.09; H, 6.45; N, 8.60; O, 23.85

Price and Availability

Size	Price	Availability
50mg	USD 450.00	2 Weeks
100mg	USD 750.00	2 Weeks
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,650.00	2 Weeks
1g	USD 3,850.00	2 Weeks
2g	USD 6,450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

LY303366; LY-303366; LY 303366; Anidulafungin; VEchinocandin; Brand name: Eraxis; Ecalta; VER-002; VER002; VER 002

IUPAC/Chemical Name

N-((2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-23-((1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl)-2,11,12,15-tetrahydroxy-6,20-bis((R)-1-hydroxyethyl)-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl)-4''-(pentyloxy)-[1,1':4',1''-terphenyl]-4-carboxamide

InChi Key

JHVAMHSQVVQIOT-DJLNKZBGSA-N

InChi Code

InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30-,31-,39+,41+,42-,43+,44-,45-,46-,47-,48-,49-,50+,54+/m0/s1

SMILES Code

CCCCCOC1=CC=C(C2=CC=C(C3=CC=C(C(N[C@@H]4C[C@@H](O)[C@@H](O)NC([C@@H]5[C@@H](O)[C@@H](C)CN5C([C@H]([C@@H](O)C)NC([C@H]([C@@H](O)[C@@H](O)C6=CC=C(O)C=C6)NC([C@@H]7C[C@@H](O)CN7C([C@H]([C@@H](O)C)NC4=O)=O)=O)=O)=O)=O)=O)C=C3)C=C2)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO.

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Anidulafungin was originally manufactured and submitted for FDA approval by Vicuron Pharmaceuticals. Pfizer acquired the drug upon its acquisition of Vicuron in the fall of 2005. Pfizer gained approval by the Food and Drug Administration (FDA) on February 21, 2006.

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,140.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Galdino da Silva KJ, Lucini F, Corrêa Dos Santos RA, Santos DA, Meis JF, de Souza Carvalho Melhem M, Teixeira de Aguiar Peres N, Bastos RW, Rossato L. How does antifungal resistance vary in Candida (Candidozyma) auris and its clades? Quantitative and qualitative analyses and their clinical implications. Clin Microbiol Infect. 2025 Apr 9:S1198-743X(25)00163-6. doi: 10.1016/j.cmi.2025.04.003. Epub ahead of print. PMID: 40216246. 2: El Nouwar R, Larranaga Lapique E, Vanden Eynden F, Martiny D, Remmelink M, Roussoulières A, Hites M. Case Report: Heart Transplantation for Refractory Candida tropicalis Endocarditis: A Case Report and Literature Review. Microorganisms. 2025 Mar 4;13(3):580. doi: 10.3390/microorganisms13030580. PMID: 40142472; PMCID: PMC11945179. 3: Ceballos-Garzon A, Holzapfel M, Welsch J, Mercer D. Identification and antifungal susceptibility patterns of reference yeast strains to novel and conventional agents: a comparative study using CLSI, EUCAST and Sensititre YeastOne methods. JAC Antimicrob Resist. 2025 Mar 19;7(2):dlaf040. doi: 10.1093/jacamr/dlaf040. PMID: 40110552; PMCID: PMC11920621. 4: Castanheira M, Deshpande LM, Kimbrough JH, Winkler M. Activity of Rezafungin Against Echinocandin Non-wild type Candida glabrata Clinical Isolates From a Global Surveillance Program. Open Forum Infect Dis. 2025 Mar 3;12(3):ofae702. doi: 10.1093/ofid/ofae702. PMID: 40046885; PMCID: PMC11879162. 5: Novak Babič M, Gunde-Cimerman N. Potable water as a source of intermediate and borderline-resistant Aspergillus and Candida strains. J Water Health. 2025 Feb;23(2):225-237. doi: 10.2166/wh.2025.300. Epub 2025 Jan 23. PMID: 40018964. 6: Ucar YA, Guven O, Genc GE. Identification of Candida glabrata complex strains isolated from clinical specimens at the species level by molecular methods and determination of their susceptibilities to antifungals. New Microbiol. 2024 Dec;47(4):344-349. PMID: 39998398. 7: Sulik-Tyszka B, Małyszko J, Pęczuła A, Jarzynka S. Moesziomyces aphidis Bloodstream Infection in Oncologic Patient: First Report in Poland. J Fungi (Basel). 2025 Jan 24;11(2):95. doi: 10.3390/jof11020095. PMID: 39997389; PMCID: PMC11856704. 8: Ramos LS, Barbosa PF, Lorentino CMA, Lima JC, Braga AL, Lima RV, Giovanini L, Casemiro AL, Siqueira NLM, Costa SC, Rodrigues CF, Roudbary M, Branquinha MH, Santos ALS. The multidrug-resistant Candida auris, Candida haemulonii complex and phylogenetic related species: Insights into antifungal resistance mechanisms. Curr Res Microb Sci. 2025 Jan 28;8:100354. doi: 10.1016/j.crmicr.2025.100354. PMID: 39995443; PMCID: PMC11847750. 9: Cornely OA, Dupont H, Mikulska M, Rautemaa-Richardson R, Garcia-Vidal C, Thompson GR 3rd, Hoenigl M. Rezafungin in special populations with candidaemia and/or invasive candidiasis. J Infect. 2025 Mar;90(3):106435. doi: 10.1016/j.jinf.2025.106435. Epub 2025 Feb 5. PMID: 39921063. 10: Vrijders L, Ho E, Van der Beek D, Vrelust I, Nailis H. More than meets the eye: Nocardia farcinica, Candida dubliniensis and Aspergillus spp. co-infection in a patient with multiple myeloma treated with multiple treatment regimens. BMC Infect Dis. 2025 Feb 3;25(1):156. doi: 10.1186/s12879-024-10387-z. PMID: 39901105; PMCID: PMC11789363. 11: Nascimento T, Inácio J, Guerreiro D, Diaz P, Patrício P, Proença L, Toscano C, Barroso H. Susceptibility patterns of Candida species collected from intensive care units in Portugal: a prospective study in 2020-2022. Infect Prev Pract. 2024 Sep 24;6(4):100403. doi: 10.1016/j.infpip.2024.100403. PMID: 39886460; PMCID: PMC11780368. 12: Maffía SA, Goyeneche B, Sormani MI, Esposto S. Mucormycosis in a child with acute lymphoblastic leukemia: Case report. Arch Argent Pediatr. 2025 Jan 30:e202410544. English, Spanish. doi: 10.5546/aap.2024-10544.eng. Epub ahead of print. PMID: 39878436. 13: Jiang K, Luo P, Wang X, Song P, Chen J, Lu L. Clarification of the biosynthetic gene cluster involved in the antifungal prodrug echinocandin B and its robust production in engineered Aspergillus pachycristatus. Microbiol Res. 2025 Apr;293:128069. doi: 10.1016/j.micres.2025.128069. Epub 2025 Jan 16. PMID: 39847892. 14: Winkler ML, Deshpande L, Kimbrough JH, Karr M, Rhomberg P, Klauer AL, Castanheira M. Anidulafungin is a useful surrogate marker for predicting in vitro susceptibility to rezafungin among five Candida species using CLSI methods and interpretive criteria. J Clin Microbiol. 2025 Feb 19;63(2):e0112924. doi: 10.1128/jcm.01129-24. Epub 2025 Jan 22. PMID: 39840977; PMCID: PMC11837505. 15: Dermitzaki N, Balomenou F, Gialamprinou D, Giapros V, Rallis D, Baltogianni M. Perspectives on the Use of Echinocandins in the Neonatal Intensive Care Unit. Antibiotics (Basel). 2024 Dec 12;13(12):1209. doi: 10.3390/antibiotics13121209. PMID: 39766599; PMCID: PMC11672459. 16: Smithgall MC, Kilic A, Weidmann M, Ofori K, Gu Y, Koganti L, Mi S, Xia H, Shi J, Pang J, Mansukhani M, Hsiao S, Wu F. Genetic and Phenotypic Intra-Clade Variation in Candida auris Isolated from Critically Ill Patients in a New York City Tertiary Care Center. Clin Chem. 2025 Jan 3;71(1):185-191. doi: 10.1093/clinchem/hvae185. PMID: 39749502. 17: Alsowaida YS, Alshoumr B, Alowais SA, Bin Saleh K, Alshammari A, Alshurtan K, Wali HA. Effectiveness and safety of echinocandins combination therapy with the standard of care compared to the standard of care monotherapy for the treatment of invasive aspergillosis infection: a meta-analysis. Front Pharmacol. 2024 Dec 19;15:1500529. doi: 10.3389/fphar.2024.1500529. PMID: 39749205; PMCID: PMC11694324. 18: König C, Frey O, Himmelein S, Mulack L, Brinkmann A, Perez Ruiz de Garibay A, Bingold T. In vitro elimination of antimicrobials during ADVanced Organ Support hemodialysis. Front Pharmacol. 2024 Dec 16;15:1447511. doi: 10.3389/fphar.2024.1447511. PMID: 39737068; PMCID: PMC11682888. 19: Skóra M, Rosam K, Namysł M, Sepioło A, Gajda M, Jędras J, Krzyściak P, Zorska J, Wordliczek J, Heczko PB, Würzner R, Lackner M, Wójkowska-Mach J. Candida albicans Horizontal Transmission in COVID-19 Patients Hospitalized in Intensive Care Unit. J Fungi (Basel). 2024 Dec 13;10(12):864. doi: 10.3390/jof10120864. PMID: 39728360; PMCID: PMC11677274. 20: Albanell-Fernández M. Echinocandins Pharmacokinetics: A Comprehensive Review of Micafungin, Caspofungin, Anidulafungin, and Rezafungin Population Pharmacokinetic Models and Dose Optimization in Special Populations. Clin Pharmacokinet. 2025 Jan;64(1):27-52. doi: 10.1007/s40262-024-01461-5. Epub 2024 Dec 21. PMID: 39707078; PMCID: PMC11762474.